Genenta presents at ASGCT preliminary pre-clinical and clinical data from Temferon™ Phase 1/2 study in patients with glioblastoma multiforme
Genenta presents at ASGCT preliminary pre-clinical and clinical data from Temferon™ Phase 1/2 study in patients with glioblastoma multiforme
May 15, 2020
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they presented preliminary pre-clinical and clinical data from the TEM-GBM_001 clinical trial at the international scientific meeting: American Society of Gene & Cell Therapy (ASGCT).
Dr Bernhard Gentner, Co-Founder of Genenta, presented relevant pre-clinical and clinical data from TEM-GBM_001 study:
- Pre-clinical results support the rational of taking Temferon™ to the clinic with the aim of breaking immune tolerance of tumors.
- Preliminary clinical results showed no dose-limiting toxicities, no systemic Interferon-alpha (IFNa) side effects, successful Temferon™ engraftment and the follow-up analysis will evaluate the efficacy and biological activity.